Neuroscience
From The Seattle Times:
The article discusses some successes and challenges to success in this field, including vignettes about Saegis Pharmaceuticals (Alzheimer disease and cognitive loss), Micrus Endovascular (surgical interventions), BioCentral Systems, and Pain Therapeutics.
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Business World: R&d Spending
A report from BusinessWeek from 27 August 2009: Drug, Biotech Research Spending Hangs Tough Overall U.S. corporate R&D spending is down 4% since the end of 2007, but some companies have chosen to buck the trend By Emily Thornton and Frederick Jespersen...
- The Game Brain
Yep - another fine New York Times interview about neuro gymnastics: Boomers, Exercise Your Brains, or Else You’ll...Uh... By KATIE HAFNER Published: May 3, 2008 "The fear of a decaying brain has inspired a mini-industry of products from dietary supplements...
- Business World: Myriad Genetics, Flurizan (mpc-7869), And Alzheimer Disease
From the AP, via Yahoo! News: Largest-Ever Alzheimer's Drug Trial Begins By PAUL ELIAS, AP Biotechnology Writer Sun Mar 12, 6:58 AM ET SAN FRANCISCO - It's tragedy enough that Pat Williams' mother...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Avonex (interferon Beta-1a)
From: RTE Ireland:Elan releases Tysabri trial figures July 19, 2005 11:09 Pharmaceutical company Elan has released figures showing that its suspended Tysabri drug improved the effectiveness of Biogen's Avonex in the treatment of multiple sclerosis....
- Business World: Australia's Cogstate
An article from the Australian website, The Age: CogState promotes brain tests to draw takeover offers By Rebecca Urban September 22, 2004 Frustrated by its diminishing value on the Australian sharemarket, diagnostic maker CogState is pitching...
Neuroscience
Business World: "The Brain Industry"
From The Seattle Times:
Biotech Watch: Biotech companies scramble to develop brain-related products[ ... Read the full article ... ]
By Steve Johnson
Knight Ridder Newspapers
The Seattle Times
Monday, July 25, 2005
SAN JOSE, Calif. — The prospect of a billion people nearing the age when they risk brain-related illnesses like Alzheimer's disease or chronic pain is helping fuel a costly scramble by biotechnology firms to find solutions.
The San Francisco Bay Area has more than 30 companies, out of about 300 worldwide, developing brain-related products for everything from sleep and anxiety disorders to multiple sclerosis and stroke. Much of the focus of "the brain industry," as it is dubbed, is on finding treatments for ailments likely to hit aging baby boomers.
The article discusses some successes and challenges to success in this field, including vignettes about Saegis Pharmaceuticals (Alzheimer disease and cognitive loss), Micrus Endovascular (surgical interventions), BioCentral Systems, and Pain Therapeutics.
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Business World: R&d Spending
A report from BusinessWeek from 27 August 2009: Drug, Biotech Research Spending Hangs Tough Overall U.S. corporate R&D spending is down 4% since the end of 2007, but some companies have chosen to buck the trend By Emily Thornton and Frederick Jespersen...
- The Game Brain
Yep - another fine New York Times interview about neuro gymnastics: Boomers, Exercise Your Brains, or Else You’ll...Uh... By KATIE HAFNER Published: May 3, 2008 "The fear of a decaying brain has inspired a mini-industry of products from dietary supplements...
- Business World: Myriad Genetics, Flurizan (mpc-7869), And Alzheimer Disease
From the AP, via Yahoo! News: Largest-Ever Alzheimer's Drug Trial Begins By PAUL ELIAS, AP Biotechnology Writer Sun Mar 12, 6:58 AM ET SAN FRANCISCO - It's tragedy enough that Pat Williams' mother...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Avonex (interferon Beta-1a)
From: RTE Ireland:Elan releases Tysabri trial figures July 19, 2005 11:09 Pharmaceutical company Elan has released figures showing that its suspended Tysabri drug improved the effectiveness of Biogen's Avonex in the treatment of multiple sclerosis....
- Business World: Australia's Cogstate
An article from the Australian website, The Age: CogState promotes brain tests to draw takeover offers By Rebecca Urban September 22, 2004 Frustrated by its diminishing value on the Australian sharemarket, diagnostic maker CogState is pitching...